Get the Stockscreener App
0.5111
0.89%
0.0045
Propanc Biopharma Inc stock is traded at $0.5111, with a volume of 106.96K.
It is up +0.89% in the last 24 hours and down -39.10% over the past month.
Propanc Biopharma Inc is a development-stage healthcare company. It focuses on developing new cancer treatments for patients suffering from pancreatic, ovarian, and colorectal cancer. The company develops a rational, composite formulation of the anti-cancer compound, which together exert a number of effects designed to control or prevent tumors from recurring and spreading through the body. Its product, PRP, is a variation upon its novel formulation and involves proenzymes, the inactive precursors of enzymes.
See More
Previous Close:
$0.5066
Open:
$0.5199
24h Volume:
106.96K
Relative Volume:
0.43
Market Cap:
$6.83M
Revenue:
-
Net Income/Loss:
$-58.92M
P/E Ratio:
-0.0111
EPS:
-45.8429
Net Cash Flow:
$-401.10K
1W Performance:
-4.75%
1M Performance:
-39.10%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$0.51
$0.5413
1-Week Range:
$0.5049
$0.6151
52-Week Range:
$0.50
$9.36
Propanc Biopharma Inc Stock (PPCB) Company Profile
Name
Propanc Biopharma Inc
Sector
Industry
Phone
61-03-9882-0780
Address
302/6 BUTLER STREET, CAMBERWELL, VICTORIA
Compare PPCB with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PPCB
Propanc Biopharma Inc
|
2.87 | 244.39K | 0 | 0 | 0 | 0.00 |
|
MOBBW
Mobilicom Limited Warrants
|
3.39 | 4.30B | 0 | 0 | 0 | 0.00 |
|
GOODO
Gladstone Commercial Corporation
|
20.92 | 372.90M | 0 | 0 | 0 | 0.00 |
|
PSNYW
Polestar Automotive Holding Uk
|
4.84 | 340.50M | 2.07B | -1.42B | -1.37B | -0.6765 |
|
SHMD
Schmid Group N V
|
7.50 | 314.36M | 0 | 0 | 0 | 0.00 |
|
DWLD
Davis Select Worldwide ETF
|
47.57 | 0 | 0 | 0 | 0 | 0.00 |
Propanc Biopharma Inc Stock (PPCB) Latest News
Propanc Biopharma Receives Nasdaq Minimum Bid Price Notice - TipRanks
Propanc Biopharma Received Notice of Noncompliance - TradingView — Track All Markets
Propanc Biopharma (NASDAQ: PPCB) details 2M-share Series C resale - Stock Titan
Propanc Biopharma files prospectus for resale of 2 million shares by selling stockholderSEC filing - MarketScreener
When Wall Street Rotates, Biotech Innovators Emerge: The Untapped Opportunities in Oncology - The Globe and Mail
Propanc Biopharma Publishes Impact of Proenzymes on Pancreatic Ductal Adenocarcinoma Fibroblasts in Peer Reviewed Journal - The Manila Times
Study tests enzyme mix that may disrupt deadly pancreatic tumors' support cells - Stock Titan
Propanc Biopharma, Inc. (PPCB) Stock Forecast & Price Prediction 2025–2030 - CoinCodex
Propanc Biopharma Shares Gain After Seeking Patent Protection for New Cancer and Fibrosis Treatments - MSN
Propanc Biopharma Inc. (PPCB) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Propanc Biopharma, Inc. (PPCB) -6.3% in After-hours: Shares Slide Amid Investigation Announcement - Stocks Telegraph
Propanc Biopharma Investigates 'Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) targets fibrosis, cancer via PRP EMT research - Stock Titan
Propanc Biopharma Investigates “Mesenchymal Drift” to Reverse Chronic Diseases Defined by Altos Labs - FinancialContent
Views of Wall Street’s Leading Experts on Propanc Biopharma Inc - setenews.com
Propanc Biopharma (PPCB) Stock Analysis Report | Financials & Insights - Benzinga
Propanc Biopharma files patents for resistant cancer and fibrosis treatments By Investing.com - Investing.com Australia
Propanc Biopharma stock rises after filing for patents to treat resistant cancer By Investing.com - Investing.com South Africa
Propanc Biopharma stock rises after filing for patents to treat resistant cancer - Investing.com Australia
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant Cancer and Fibrosis - The Manila Times
Propanc Biopharma files patents for resistant cancer and fibrosis treatments - Investing.com
Propanc Biopharma Requests Foreign Filing License from Spain for Methods of Treating Resistant ... - Enidnews.com
Propanc Biopharma (Nasdaq: PPCB) moves to patent PRP use in fibrosis ahead of 2026 Phase 1b trial - Stock Titan
Propanc Biopharma secures up to $100 million private placement - MSN
Propanc Biopharma Inc Share PricePPCB, RNS News, Articles, Quotes, & Charts (OTCMKTS:PPCB) - Proactive financial news
Australian firm launches crypto treasury for the future of cancer drug - Proactive financial news
Propanc Biopharma Provides Corporate Update and Reports First Quarter 2025/26 Results - The Manila Times
Propanc Biopharma (Nasdaq: PPCB) Raises $4M, Lists on Nasdaq, Sets $100M Facility - Stock Titan
Propanc Biopharma, Inc. SEC 10-Q Report - TradingView
Propanc Biopharma Secures $1M Through Stock Sale - MSN
Propanc Biopharma Secures $100M Crypto Deal for Cancer Breakthrough - Analytics Insight
Propanc Biopharma Secures Up to $100M to Build Crypto Treasury and Advance Cancer Therapy Trials - Bitget
The time has not yet come to remove your chips from the table: Propanc Biopharma Inc (PPCB) - setenews.com
Propanc Biopharma (PPCB) Stock: Crypto Treasury Plan Triggers Massive Sell-Off - parameter.io
Propanc Biopharma (PPCB) Stock: Biotech Secures $100M Crypto Funding as Shares Tumble - Blockonomi
Propanc, The Australian Biotech, Turns To Crypto To Tackle Cancer - Bitcoinist.com
Propanc Biopharma (PPCB) Stock: Company Secures $100M Crypto Treasury Deal - CoinCentral
Propanc Biopharma secures up to $100 million investment from Hexstone By Investing.com - Investing.com Nigeria
Propanc Biopharma secures $1 million initial investment from Hexstone By Investing.com - Investing.com Nigeria
Propanc Biopharma Secures $100M to Build Crypto Treasury - Coinpaper
Bitcoin News Update: Propanc’s Cryptocurrency-Driven Cancer Initiative Encounters Doubt from Investors, Stock Falls by 10.5% - Bitget
Biopharma raises $100M for crypto treasury to back cancer treatment - TradingView
[8-K] Propanc Biopharma, Inc. Reports Material Event | PPCB SEC FilingForm 8-K - Stock Titan
Biotech firm Propanc lines up $100 million to fund crypto treasury and cancer therapy push - TradingView
Propanc Biopharma, Inc. announced that it has received $1 million in funding from Hexstone Capital, LLC - MarketScreener
Propanc Biopharma Inc Stock (PPCB) Financials Data
Revenue
Net Income
Cash Flow
EPS
28.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):